Curtis Triplitt

3.8k total citations
89 papers, 2.7k citations indexed

About

Curtis Triplitt is a scholar working on Endocrinology, Diabetes and Metabolism, Molecular Biology and Surgery. According to data from OpenAlex, Curtis Triplitt has authored 89 papers receiving a total of 2.7k indexed citations (citations by other indexed papers that have themselves been cited), including 73 papers in Endocrinology, Diabetes and Metabolism, 41 papers in Molecular Biology and 36 papers in Surgery. Recurrent topics in Curtis Triplitt's work include Diabetes Treatment and Management (63 papers), Metabolism, Diabetes, and Cancer (39 papers) and Diabetes Management and Research (33 papers). Curtis Triplitt is often cited by papers focused on Diabetes Treatment and Management (63 papers), Metabolism, Diabetes, and Cancer (39 papers) and Diabetes Management and Research (33 papers). Curtis Triplitt collaborates with scholars based in United States, Italy and Finland. Curtis Triplitt's co-authors include Eugênio Cersósimo, Ralph A. DeFronzo, Carolina Solis‐Herrera, Ralph A. DeFronzo, John M. Adams, Leonard C. Glass, Estela Wajcberg, Lawrence J. Mandarino, Y. Miyazaki and Muhammad Abdul-Ghani and has published in prestigious journals such as Journal of the American College of Cardiology, Hepatology and The Journal of Clinical Endocrinology & Metabolism.

In The Last Decade

Curtis Triplitt

86 papers receiving 2.6k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Curtis Triplitt United States 30 1.8k 1.1k 834 527 436 89 2.7k
Susan L. Samson United States 25 1.7k 0.9× 677 0.6× 735 0.9× 436 0.8× 654 1.5× 82 3.0k
Teresa Vanessa Fiorentino Italy 28 1.7k 0.9× 1.1k 1.0× 750 0.9× 681 1.3× 783 1.8× 109 3.3k
Roy Eldor Israel 24 1.8k 1.0× 1.1k 1.0× 1.1k 1.4× 405 0.8× 359 0.8× 70 2.9k
Steven C. Griffen United States 28 1.8k 1.0× 888 0.8× 1.1k 1.3× 707 1.3× 639 1.5× 42 3.0k
Andrej Janež Slovenia 35 2.3k 1.3× 1.1k 1.0× 869 1.0× 564 1.1× 466 1.1× 179 4.4k
H Yki-Järvinen Finland 26 1.8k 1.0× 996 0.9× 706 0.8× 764 1.4× 681 1.6× 38 3.3k
Nanwei Tong China 25 1.1k 0.6× 779 0.7× 407 0.5× 323 0.6× 300 0.7× 124 2.4k
Jeffrey W. Stephens United Kingdom 33 913 0.5× 1.1k 1.0× 647 0.8× 999 1.9× 420 1.0× 139 3.3k
Muhammad Abdul-Ghani United States 31 2.4k 1.3× 1.9k 1.8× 827 1.0× 1.1k 2.0× 807 1.9× 49 4.3k
Pierre Maheux Canada 26 1.5k 0.8× 412 0.4× 621 0.7× 660 1.3× 415 1.0× 51 2.6k

Countries citing papers authored by Curtis Triplitt

Since Specialization
Citations

This map shows the geographic impact of Curtis Triplitt's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Curtis Triplitt with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Curtis Triplitt more than expected).

Fields of papers citing papers by Curtis Triplitt

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Curtis Triplitt. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Curtis Triplitt. The network helps show where Curtis Triplitt may publish in the future.

Co-authorship network of co-authors of Curtis Triplitt

This figure shows the co-authorship network connecting the top 25 collaborators of Curtis Triplitt. A scholar is included among the top collaborators of Curtis Triplitt based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Curtis Triplitt. Curtis Triplitt is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Cersósimo, Eugênio, et al.. (2024). Effect of dapagliflozin on renal haemodynamics in hyperfiltering T2D patients. Diabetes Obesity and Metabolism. 27(2). 944–952. 2 indexed citations
2.
Merovci, Aurora, et al.. (2024). Effect of weight-maintaining ketogenic diet on glycemic control and insulin sensitivity in obese T2D subjects. BMJ Open Diabetes Research & Care. 12(5). e004199–e004199. 11 indexed citations
3.
Cersósimo, Eugênio, Carolina Solis‐Herrera, & Curtis Triplitt. (2024). Current Risk Management Strategies in Type 2 Diabetes. 1–11. 1 indexed citations
4.
Peterson, Richard E., Curtis Triplitt, Geoffrey D. Clarke, et al.. (2024). Mesenteric Visceral Lipectomy Improves Glucose Tolerance in Patients With Type 2 Diabetes: A Pilot Study. The Journal of Clinical Endocrinology & Metabolism. 110(9). e3070–e3077. 2 indexed citations
5.
6.
Solis‐Herrera, Carolina & Curtis Triplitt. (2023). Non‐steroidal mineralocorticoid receptor antagonists in patients with chronic kidney disease and type 2 diabetes. Diabetes Obesity and Metabolism. 26(2). 417–430. 6 indexed citations
7.
Solis‐Herrera, Carolina, Michael P. Kane, & Curtis Triplitt. (2023). Current Understanding of Sodium N-(8-[2-Hydroxylbenzoyl] Amino) Caprylate (SNAC) as an Absorption Enhancer: The Oral Semaglutide Experience. Clinical Diabetes. 42(1). 74–86. 12 indexed citations
8.
Cersósimo, Eugênio, Carolina Solis‐Herrera, Michael Trautmann, Jaret Malloy, & Curtis Triplitt. (2014). Assessment of Pancreatic β-Cell Function: Review of Methods and Clinical Applications. Current Diabetes Reviews. 10(1). 2–42. 194 indexed citations
9.
Abdul‐Ghani, Muhammad, Curtiss Puckett, John M. Adams, et al.. (2013). 1.8 Initial Triple Combination Therapy is Superior to Stepwise Add-On Conventional Therapy in Newly Diagnosed T2DM (72-OR). 11(3). 80–81. 7 indexed citations
10.
Cersósimo, Eugênio, Amalia Gastaldelli, Áurea Cervera, et al.. (2011). Effect of Exenatide on Splanchnic and Peripheral Glucose Metabolism in Type 2 Diabetic Subjects. The Journal of Clinical Endocrinology & Metabolism. 96(6). 1763–1770. 43 indexed citations
11.
Gastaldelli, Amalia, Curtis Triplitt, Jean Hardies, et al.. (2011). Metabolic effects of muraglitazar in type 2 diabetic subjects. Diabetes Obesity and Metabolism. 13(10). 893–902. 13 indexed citations
12.
Triplitt, Curtis. (2010). Improving treatment success rates for type 2 diabetes: recommendations for a changing environment.. PubMed. 16(7 Suppl). S195–200. 20 indexed citations
13.
Wajcberg, Estela, Apiradee Sriwijitkamol, Curtis Triplitt, et al.. (2008). Mechanism of action of exenatide to reduce postprandial hyperglycemia in type 2 diabetes. American Journal of Physiology-Endocrinology and Metabolism. 294(5). E846–E852. 127 indexed citations
14.
Triplitt, Curtis. (2007). How to initiate, titrate, and intensify insulin treatment in type 2 diabetes. 32(10). 10–16. 3 indexed citations
15.
Miyazaki, Y., Eugênio Cersósimo, Curtis Triplitt, & Ralph A. DeFronzo. (2007). Rosiglitazone decreases albuminuria in type 2 diabetic patients. Kidney International. 72(11). 1367–1373. 92 indexed citations
16.
Triplitt, Curtis, Janet B. McGill, Daniel Porte, & Christopher S. Conner. (2007). The Changing Landscape of Type 2 Diabetes: The Role of Incretin-Based Therapies in Managed Care Outcomes. Journal of Managed Care Pharmacy. 13(9 Supp C). 1–17. 30 indexed citations
17.
Rosenstock, Julio, et al.. (2006). What Are Incretins, and How Will They Influence the Management of Type 2 Diabetes?. Journal of Managed Care Pharmacy. 12(7 Supp A). 1–16. 12 indexed citations
18.
Triplitt, Curtis, Alison K. Wright, & Elaine Chiquette. (2006). Incretin Mimetics and Dipeptidyl Peptidase‐IV Inhibitors: Potential New Therapies for Type 2 Diabetes Mellitus. Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy. 26(3). 360–374. 32 indexed citations
19.
Triplitt, Curtis & Elaine Chiquette. (2006). Exenatide: From the Gila Monster to the Pharmacy. Journal of the American Pharmacists Association. 46(1). 44–55. 46 indexed citations
20.
Triplitt, Curtis & Ralph A. DeFronzo. (2006). Exenatide: first-in-class incretin mimetic for the treatment of Type 2 diabetes mellitus. Expert Review of Endocrinology & Metabolism. 1(3). 329–341. 22 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Susan L. Samson Breakdown of academic impact, for papers by Teresa Vanessa Fiorentino Breakdown of academic impact, for papers by Roy Eldor Breakdown of academic impact, for papers by Steven C. Griffen Breakdown of academic impact, for papers by Andrej Janež Breakdown of academic impact, for papers by H Yki-Järvinen Breakdown of academic impact, for papers by Nanwei Tong Breakdown of academic impact, for papers by Jeffrey W. Stephens Breakdown of academic impact, for papers by Muhammad Abdul-Ghani Breakdown of academic impact, for papers by Pierre Maheux
Rankless by CCL
2026